loader from loading.io

Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer

Speaking of SurgOnc

Release Date: 06/14/2022

ASO Series: Targeting Patient-Derived Orthotopic Gastric Cancers with a Fluorescent Humanized Anti-CEA Antibody show art ASO Series: Targeting Patient-Derived Orthotopic Gastric Cancers with a Fluorescent Humanized Anti-CEA Antibody

Speaking of SurgOnc

Speaking of SurgOnc has a new home! New episodes can now be found under the Society of Surgical Oncology's podcast, SurgOnc Today, available on all major podcast platforms. Subscribe today to receive updates on new episode releases.  In this new episode of Speaking of SurgOnc, Dr. Rick Greene discusses with Dr. Michael Bouvet and Dr. Kristin Cox the applicability of M5A-IR800 to target human gastric cancer, as reported in their article, "Targeting Patient-Derived Orthotopic Gastric Cancers with a Fluorescent Humanized Anti-CEA Antibody."

info_outline
ASO Series: A Four-Arm Randomized Clinical Trial of Topical Pain Control for Sentinel Node Radiotracer Injections in Patients with Breast Cancer show art ASO Series: A Four-Arm Randomized Clinical Trial of Topical Pain Control for Sentinel Node Radiotracer Injections in Patients with Breast Cancer

Speaking of SurgOnc

Dr. Rick Greene discusses with Dr. Heather Neuman and Dr. Alyssa Wiener the results of a randomized trial of topical pain approaches for radiotracer injections for breast cancer sentinel lymph node mapping, as reported in her article, "A Four-Arm Randomized Clinical Trial of Topical Pain Control for Sentinel Node Radiotracer Injections in Patients with Breast Cancer.”

info_outline
Adjuvant Chemoradiation in Resected Biliary Adenocarcinoma: Evaluation of SWOG S0809 with a Large National Database show art Adjuvant Chemoradiation in Resected Biliary Adenocarcinoma: Evaluation of SWOG S0809 with a Large National Database

Speaking of SurgOnc

Dr. Rick Greene discusses with Dr. Dana Dominguez the association of adjuvant chemoradiation in resected biliary cancer with improved overall survival compared to chemotherapy alone, as reported in her article, "Adjuvant Chemoradiation in Resected Biliary Adenocarcinoma: Evaluation of SWOG S0809 with a Large National Database.”

info_outline
SSO2024 Abstract: Lower Social Support Predicts Higher Cortisol for Breast Cancer Patients in Disadvantaged Neighborhoods show art SSO2024 Abstract: Lower Social Support Predicts Higher Cortisol for Breast Cancer Patients in Disadvantaged Neighborhoods

Speaking of SurgOnc

Dr. Rick Greene discusses with Dr. Alexandra Hernandez the role of social support and neighborhood disadvantage on cortisol, a physiologic marker of stress in patients with breast cancer, as reported at the 2024 SSO Meeting in her abstract, "Lower Social Support Predicts Higher Cortisol for Breast Cancer Patients in Disadvantaged Neighborhoods.”

info_outline
Practice Patterns and Outcomes Among Surgical Oncology Fellowship Graduates Performing Complex Cancer Surgery in the United States Across Different Career Stages show art Practice Patterns and Outcomes Among Surgical Oncology Fellowship Graduates Performing Complex Cancer Surgery in the United States Across Different Career Stages

Speaking of SurgOnc

Dr. Rick Greene discusses with Dr. Timothy Pawlik and Dr. Diamantis Tsilimigras the assessment of perioperative mortality and serious complications among patients undergoing complex cancer surgery by surgical oncology fellowship graduates across different career stages. Dr. Pawlik and Dr. Tsilimigras are co-authors of "Practice Patterns and Outcomes Among Surgical Oncology Fellowship Graduates Performing Complex Cancer Surgery in the United States Across Different Career Stages."

info_outline
Extent of Resection and Long-Term Outcomes for Appendiceal Adenocarcinoma: a SEER Database Analysis of Mucinous and non-Mucinous Histologies show art Extent of Resection and Long-Term Outcomes for Appendiceal Adenocarcinoma: a SEER Database Analysis of Mucinous and non-Mucinous Histologies

Speaking of SurgOnc

Dr. Rick Greene discusses with Dr. Brett Ecker the association between extent of resection and disease-specific survival  in mucinous and non-mucinous appendiceal adenocarcinomas as reported in his article, "Extent of Resection and Long-Term Outcomes for Appendiceal Adenocarcinoma: a SEER Database Analysis of Mucinous and non-Mucinous Histologies.”

info_outline
Docetaxel‑Based Neoadjuvant Chemotherapy Followed by En Bloc Resection for Esophageal Adenocarcinoma: A 15‑Year Retrospective Analysis from a Regional Upper Gastrointestinal Cancer Network show art Docetaxel‑Based Neoadjuvant Chemotherapy Followed by En Bloc Resection for Esophageal Adenocarcinoma: A 15‑Year Retrospective Analysis from a Regional Upper Gastrointestinal Cancer Network

Speaking of SurgOnc

Rick Greene, MD, discusses with Lorenzo Ferri, MD, PhD, the long-term survival outcomes of patients with esophageal and junctional adenocarcinoma treated with neoadjuvant docetaxel-based chemotherapy and en bloc transthoracic esophagectomy. Dr. Ferri is author of, "Docetaxel-Based Neoadjuvant Chemotherapy Followed by En Bloc Resection for Esophageal Adenocarcinoma: A 15-Year Retrospective Analysis from a Regional Upper Gastrointestinal Cancer Network." Dr. Ferri is Professor of Surgery and Oncology, McGill University; David S. Mulder Chair of Surgery Head, Division of Thoracic and Upper...

info_outline
The Landmark Series—Addressing Disparities in Breast Cancer Screening: New Recommendations for Black Women show art The Landmark Series—Addressing Disparities in Breast Cancer Screening: New Recommendations for Black Women

Speaking of SurgOnc

Rick Greene, MD, discusses with Kathie-Ann Joseph, MD, MPH, the epidemiologic and socioeconomic factors that are associated with breast cancer among black women and an assessment of the implications of these factors for screening in this population. Dr. Joseph is author of, "The Landmark Series—Addressing Disparities in Breast Cancer Screening: New Recommendations for Black Women." Dr. Joseph is Professor, Department of Surgery at NYU Grossman School of Medicine; Professor, Department of Population Health at NYU Grossman School of Medicine; and, Vice Chair for Diversity and Health Equity for...

info_outline
Standardization of Colon Resection for Cancer: An Overview of the American College of Surgeons Commission on Cancer Standard 5.6 show art Standardization of Colon Resection for Cancer: An Overview of the American College of Surgeons Commission on Cancer Standard 5.6

Speaking of SurgOnc

Rick Greene, MD, discusses with Anthony Villano, MD, a review the American College of Surgeons Commission on Cancer Standard 5.6, which pertains to curative intent colon resections performed for cancer. Dr. Villano is author of "Standardization of Colon Resection for Cancer: An Overview of the American College of Surgeons Commission on Cancer Standard 5.6." Dr. Villano is the Assistant Professor, Surgical Oncology, in the Department of Surgical Oncology, at Fox Chase Cancer Center in Philadelphia, PA.

info_outline
Hepatectomy Before Primary Tumor Resection as Preferred Approach for Synchronous Liver Metastases from Rectal Cancer show art Hepatectomy Before Primary Tumor Resection as Preferred Approach for Synchronous Liver Metastases from Rectal Cancer

Speaking of SurgOnc

Rick Greene, MD, discusses with Jean-Nicolas Vauthey, MD, a comparison of different surgical approaches to synchronous liver metastases from rectal cancer and their analysis of both clinicopathological and biological tumor factors associated with completion of the reverse approach. Professor Vauthey is the senior author of, “Hepatectomy Before Primary Tumor Resection as Preferred Approach for Synchronous Liver Metastases from Rectal Cancer.” Dr. Vauthey is Professor of Surgery and Chief of the Hepato-Pancreato-Biliary Section, and the Dallas/Fort Worth Living Legend Chair of Cancer...

info_outline
 
More Episodes

Rick Greene, MD, and Mark Truty, MD, discuss the role of neoadjuvant chemotherapy in the treatment of pancreatic cancer, including the optimal treatment of patients who do not respond to first-line chemotherapy or develop toxicities. Dr. Truty is author of, “Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer.” Dr. Truty is Associate Professor of Surgery, Mayo Clinic, Rochester, MN, where his clinical practice is in the Division of Subspecialty General Surgery, Department of Surgery.